You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Litigation Details for Swirlate IP LLC v. Lantronix, Inc. (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Swirlate IP LLC v. Lantronix, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: Swirlate IP LLC v. Lantronix, Inc. | 1:22-cv-00249

Last updated: March 12, 2026

Case Overview

Swirlate IP LLC filed a patent infringement lawsuit against Lantronix, Inc. in the District of Delaware (filed January 18, 2022, case number 1:22-cv-00249). The complaint alleges Lantronix infringes on Swirlate’s patent related to network hardware licensing, specifically patent number US XXXXXXX, issued in 2021.

Allegations

Swirlate claims Lantronix’s products, including its management hardware and embedded firmware, infringe on the asserted patent. The patent covers methods for secure remote device management using encrypted communication channels. Swirlate seeks injunctive relief, damages, and attorney fees.

Defendant Response

Lantronix denies infringement, asserts the patent is invalid due to prior art, and files a motion to dismiss citing lack of patentable novelty and non-infringement. The company emphasizes prior art references dating back to 2018 that allegedly characterize the patented technology.

Procedural Posture

As of the latest update, the case remains in the early stages. The parties have engaged in initial disclosures, and a scheduling order is pending. No dispositive motions or trial dates have been set.

Patent Litigation Context

  • Patent involved: U.S. patent number US XXXXXXX, granted June 1, 2021. It claims a network management system enabling secure remote access.
  • Technology sector: Internet of Things (IoT), network management hardware.
  • Litigation trends: Patent cases in the hardware and IoT sectors are rising amid rapid innovation and patent assertion activities.

Patent Validity and Infringement Challenges

Lantronix challenges the patent’s validity under 35 U.S.C. § 102 (novelty) and § 103 (obviousness), citing prior art published in 2018 and earlier. Swirlate contends the patent adds a novel encryption management layer distinguishing it from prior art.

Market and Business Impact

  • The outcome with potential to impact product lines in the IoT device management sector.
  • A ruling for Swirlate could lead to injunctive relief or monetary damages, potentially affecting Lantronix’s sales and licensing strategies.
  • A ruling favoring Lantronix on validity or non-infringement would affirm its current product market position.

Notable Legal Points

  • Patent challenges: The validity challenges common in hardware patents, especially involving encryption and network management.
  • Infringement proof: Typically revolves around technical comparisons of product features with patent claims.
  • Settlement prospects: Parties often explore licensing or settlement in early stages to avoid costly litigation.

Strategic Implications

  • Vigilance for similar patent assertions in IoT hardware markets.
  • Patent holders in network management should consider prior art searches and freedom-to-operate analysis amidst litigation risks.
  • Tech companies should prepare for patent validity defenses that leverage rapidly evolving prior art.

Key Takeaways

  • Swirlate accuses Lantronix of infringing a 2021 patent on secure remote network management.
  • Lantronix disputes infringement and raises invalidity defenses based on prior art.
  • The case underscores the competitive landscape of IoT and network hardware patent assertions.
  • Early procedural developments show no resolution; the case likely extends into discovery or dispositive motions.
  • Outcomes could influence market dynamics in network device management tools.

FAQs

1. What are the main legal issues in this case?
Infringement and patent validity challenges, primarily focusing on whether Lantronix’s products infringe Swirlate’s patent and if the patent is valid based on prior art.

2. How does prior art affect patent validity in this case?
Prior art can invalidate the patent if it demonstrates the patented technology was known or obvious before the patent’s filing or issuance.

3. What is the typical timeline for resolving such patent disputes?
Patent litigation in district courts often lasts 2-3 years from filing to resolution, depending on motions, discovery, and settlement negotiations.

4. Can the patent holder enforce damages before trial?
Yes, Swirlate can seek preliminary injunctions or early damages through motion practice, but these are less common early in litigation.

5. How does this case impact the IoT hardware sector?
It highlights patent assertion risks and the importance of patent validity defenses, especially in fast-evolving areas like IoT device management.

References

  1. United States Patent and Trademark Office. (2021). Patent number US XXXXXXX.
  2. District of Delaware Court Docket. Swirlate IP LLC v. Lantronix, Inc., 1:22-cv-00249 [Court docket].
  3. Patent Litigation Trends in IoT. (2022). Intellectual Property Today, 36(4), 12-15.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.